Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Clinical Trial Analysis
4.1. Ongoing Clinical Trials
4.2. Completed Clinical Trials
4.3. Terminated Clinical Trials
4.4. Breakdown of Pipeline, By Development Phase
4.5. Breakdown of Pipeline, By Status
4.6. Breakdown of Pipeline, By Study Type
4.7. Breakdown of Pipeline, By Region
4.8. Clinical Trials Heat Map
5. Voice of Customer
6. Global mRNA Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
6.2.4. By Company (2022)
6.3. Product Map
6.3.1. By mRNA Type
6.3.2. By Application
6.3.3. By Region
7. North America mRNA Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States mRNA Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By mRNA Type
7.3.1.2.2. By Application
7.3.2. Canada mRNA Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By mRNA Type
7.3.2.2.2. By Application
7.3.3. Mexico mRNA Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By mRNA Type
7.3.3.2.2. By Application
8. Europe mRNA Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France mRNA Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By mRNA Type
8.3.1.2.2. By Application
8.3.2. Germany mRNA Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By mRNA Type
8.3.2.2.2. By Application
8.3.3. United Kingdom mRNA Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By mRNA Type
8.3.3.2.2. By Application
8.3.4. Italy mRNA Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By mRNA Type
8.3.4.2.2. By Application
8.3.5. Spain mRNA Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By mRNA Type
8.3.5.2.2. By Application
9. Asia-Pacific mRNA Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China mRNA Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By mRNA Type
9.3.1.2.2. By Application
9.3.2. India mRNA Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By mRNA Type
9.3.2.2.2. By Application
9.3.3. Japan mRNA Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By mRNA Type
9.3.3.2.2. By Application
9.3.4. South Korea mRNA Vaccine Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By mRNA Type
9.3.4.2.2. By Application
9.3.5. Australia mRNA Vaccine Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By mRNA Type
9.3.5.2.2. By Application
10. South America mRNA Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil mRNA Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By mRNA Type
10.3.1.2.2. By Application
10.3.2. Argentina mRNA Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By mRNA Type
10.3.2.2.2. By Application
10.3.3. Colombia mRNA Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By mRNA Type
10.3.3.2.2. By Application
11. Middle East and Africa mRNA Vaccine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa mRNA Vaccine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By mRNA Type
11.3.1.2.2. By Application
11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By mRNA Type
11.3.2.2.2. By Application
11.3.3. UAE mRNA Vaccine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By mRNA Type
11.3.3.2.2. By Application
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Merger Acquisition
13.3. Product launches
14. Global mRNA Vaccine Market: SWOT Analysis
15. Porter?s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
16.6.1. Arcturus Therapeutics Holdings Inc.
16.6.2. BioNTech SE
16.6.3. CureVac N.V.
16.6.4. Daiichi Sankyo Company Limited.
16.6.5. Ethris GmbH
16.6.6. GlaxoSmithKline plc
16.6.7. Gennova Biopharmaceuticals Ltd
16.6.8. Moderna, Inc.
16.6.9. Pantherna Therapeutics GmbH
16.6.10. Providence Therapeutics
16.6.11. Silence Therapeutics
16.6.12. Translate Bio
16.6.13. VERSAMEB AG
16.6.14. Verve Therapeutics Inc.
17. Strategic Recommendations